Drug intelligence / Profile preview

Hylo Grev

Development stage: Unknown
Lead developer: Grevis Pharma
Administration: Ophthalmic

Overview

Hylo Grev is a topical ophthalmic lubricant developed and marketed by Grevis Pharmaceuticals in India. Its active ingredient is sodium hyaluronate (0.1% w/v), a naturally occurring biopolymer that acts as a viscoelastic lubricant. The product is indicated for the treatment of dry eye syndrome (keratoconjunctivitis sicca) and ocular surface lubrication. It works by forming a stable, long-lasting, and moisture-retaining protective layer over the ocular surface, mimicking the function of natural tears without binding to a specific molecular receptor. The formulation is typically supplied as eye drops in a 10ml bottle and may contain sodium perborate as a preservative to maintain sterility.

Brand names: Hylo Grev
Other names: Hylo-Grev

Beyond the preview

Go deeper on Hylo Grev.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hylo Grev.

Explore the full profile